Summary: In a randomised trial in fatty liver disease with type 2 diabetes, adding ezetimibe to metformin raised expression of the metabolic genes PPAR-gamma and adiponectin and improved insulin resistance and triglycerides more than metformin alone, over six months.
PICO Summary
| Element | Detail |
|---|---|
| Population | Adults with metabolic-dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes; 6-month randomised trial, Iran. |
| Intervention | Ezetimibe plus metformin (Met+EZY). |
| Comparison | Metformin alone (Met). |
| Outcome | In the Met+EZY group, insulin, HOMA-IR, malondialdehyde, and triglycerides fell from baseline to 3 months (p<0.05), and PPAR-gamma and adiponectin gene expression rose (p<0.01). Between groups, PPAR-gamma and adiponectin expression were significantly higher with Met+EZY at 3 and 6 months (p<0.001). No serious adverse events. The authors advise the combination be used cautiously. |
Ezetimibe + metformin in MAFLD with type 2 diabetes
RCT · MAFLD + type 2 diabetes · 6 months
Adding ezetimibe to metformin raised PPAR-gamma and adiponectin expression and lowered insulin resistance and triglycerides more than metformin alone. Endpoints are surrogate molecular and biochemical markers, so the signal is mechanistic rather than proven clinical benefit.
Expert Commentary
This is a mechanistically interesting trial that probes how a familiar lipid-lowering drug might act on fatty-liver biology beyond cholesterol, and the gene-expression angle is its novel contribution. The findings are biologically coherent: ezetimibe added to metformin was associated with higher PPAR-gamma and adiponectin expression alongside lower insulin resistance, oxidative stress, and triglycerides, which fits a picture of improved adipose-liver crosstalk and insulin sensitisation. My main caution is about endpoint hierarchy. These are surrogate molecular and biochemical markers, gene expression in particular, rather than histological steatosis, fibrosis, or hard clinical outcomes, so the result tells us about plausible mechanism more than proven benefit, and the authors’ own note that the combination should be used cautiously is worth foregrounding. The study is also relatively small, single-region, and six months long, and reductions concentrated in the first three months without clear evidence of continued divergence afterward. Can I use this with my patients? Indirectly. It does not change my prescribing on its own, but it adds plausibility to addressing lipids and insulin resistance together in diabetic fatty-liver disease, while I would rely on established indications for ezetimibe and proven liver therapies rather than recommending it specifically for steatosis on this evidence.
References
Masaeli A, Goodarzi MT, Mohammadalipour A, Ali-Asgari S, Mirzaei MR, Hani M. Combined effect of metformin and ezetimibe on PPAR-γ and adiponectin gene expression and biochemical parameters in MAFLD patients with type 2 diabetes. Sci Rep. 2025;15(1):35884. doi:10.1038/s41598-025-19877-9